Literature DB >> 7520895

T cells recognize a peptide derived from alpha-gliadin presented by the celiac disease-associated HLA-DQ (alpha 1*0501, beta 1*0201) heterodimer.

H A Gjertsen1, K E Lundin, L M Sollid, J A Eriksen, E Thorsby.   

Abstract

CD is unique among the HLA-associated diseases since (a) the disease-promoting agent (gliadin) is known and (b) the disease is precipitated mainly in individuals carrying a particular cis- or trans-encoded HLA-DQ heterodimer; i.e., DQ(alpha 1*0501, beta 1*0201). Further, a preponderance of gliadin-specific T cells derived from the small intestinal mucosa of CD patients are restricted by this DQ heterodimer. T-cell recognition of gliadin peptides presented by the DQ(alpha 1*0501, beta 1*0201) heterodimer may thus be of importance in CD. Here we report that a T-cell clone from a patient with CD recognizes a synthetic alpha-gliadin peptide, when presented by the cis- or trans-encoded CD-associated DQ(alpha 1*0501, beta 1*0201) heterodimer. The minimal peptide recognized by the T-cell clone corresponds to residues 31-47 of alpha-gliadin, which is included in the part of alpha-gliadin previously shown to have disease-promoting activity. When testing analogue peptides derived from other alpha-gliadin sequences, one peptide differing by one amino acid was recognized by the T-cell clone, whereas the other peptide differing by two amino acids was not recognized. Our findings demonstrate that the CD-associated DQ(alpha 1*0501, beta 1*0201) heterodimer may serve as an antigen-presenting molecule to T cells for certain gliadin peptides.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7520895     DOI: 10.1016/0198-8859(94)90267-4

Source DB:  PubMed          Journal:  Hum Immunol        ISSN: 0198-8859            Impact factor:   2.850


  20 in total

1.  Getting to grips with gluten.

Authors:  S N McAdam; L M Sollid
Journal:  Gut       Date:  2000-12       Impact factor: 23.059

2.  B cell epitopes of gliadin.

Authors:  A A Osman; T Günnel; A Dietl; H H Uhlig; M Amin; B Fleckenstein; T Richter; T Mothes
Journal:  Clin Exp Immunol       Date:  2000-08       Impact factor: 4.330

3.  A novel and sensitive method for the detection of T cell stimulatory epitopes of alpha/beta- and gamma-gliadin.

Authors:  E H A Spaenij-Dekking; E M C Kooy-Winkelaar; W F Nieuwenhuizen; J W Drijfhout; F Koning
Journal:  Gut       Date:  2004-09       Impact factor: 23.059

Review 4.  Recent advances in the understanding of celiac disease: therapeutic implications for the management of pediatric patients.

Authors:  John H Kwon; Richard J Farrell
Journal:  Paediatr Drugs       Date:  2006       Impact factor: 3.022

5.  Immunopathogenesis of celiac disease.

Authors:  Jason Tye-Din; Robert Anderson
Journal:  Curr Gastroenterol Rep       Date:  2008-10

6.  Identification of common epitopes on gliadin, enterocytes, and calreticulin recognised by antigliadin antibodies of patients with coeliac disease.

Authors:  S Krupicková; L Tucková; Z Flegelová; M Michalak; J R Walters; A Whelan; J Harries; J Vencovský; H Tlaskalová-Hogenová
Journal:  Gut       Date:  1999-02       Impact factor: 23.059

7.  Down's syndrome is strongly associated with coeliac disease.

Authors:  L Gale; H Wimalaratna; A Brotodiharjo; J M Duggan
Journal:  Gut       Date:  1997-04       Impact factor: 23.059

8.  Anti-alpha-gliadin antibodies (AGA) in the serum of coeliac children and controls recognize an identical collection of linear epitopes of alpha-gliadin.

Authors:  M ten Dam; Y Van De Wal; M L Mearin; Y Kooy; S Peña; J W Drijfhout; F Koning; M Van Tol
Journal:  Clin Exp Immunol       Date:  1998-11       Impact factor: 4.330

9.  Small intestinal T cells of celiac disease patients recognize a natural pepsin fragment of gliadin.

Authors:  Y van de Wal; Y M Kooy; P A van Veelen; S A Peña; L M Mearin; O Molberg; K E Lundin; L M Sollid; T Mutis; W E Benckhuijsen; J W Drijfhout; F Koning
Journal:  Proc Natl Acad Sci U S A       Date:  1998-08-18       Impact factor: 11.205

10.  Role of T cell receptor delta gene in susceptibility to celiac disease.

Authors:  E Roschmann; T F Wienker; B A Volk
Journal:  J Mol Med (Berl)       Date:  1996-02       Impact factor: 4.599

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.